Equities

Turk Ilac ve Serum Sanayi AS

TRILC.E:IST

Turk Ilac ve Serum Sanayi AS

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TRY)29.22
  • Today's Change-0.46 / -1.55%
  • Shares traded4.95m
  • 1 Year change+218.30%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 16:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Turk Ilac ve Serum Sanayi AS is a Turkey-based pharmaceutical company. The main activity of the Company is to manufacture and sell all kinds of tablets, capsules, ampoules, vials, ointments-creams, intravenous serums, parenteral solutions, nutritional solutions, amino acids and other chemical substances. The company also acts as the representative or sales agency of other domestic and foreign pharmaceutical companies, as well as importing and marketing veterinary, cosmetics and pesticides. Turk Ilac manufactures in accordance with Current Good Manufacturing (GMP) and Good Laboratory Practice (GLP) principles with its approximately 300 employees in its facilities on a total area of 56.000 square meters in the Ankara - Akyurt region.

  • Revenue in TRY (TTM)1.91bn
  • Net income in TRY105.72m
  • Incorporated2012
  • Employees439.00
  • Location
    Turk Ilac ve Serum Sanayi ASBugduz Mah. Enver Pasa Cad. No:8 AkyurtAnkara 06750TurkeyTUR
  • Phone+90 3 128376767
  • Fax+90 3 128442106
  • Websitehttp://www.turkilac.com.tr
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arcticzymes Technologies ASA361.60m53.91m4.00bn68.0074.354.1554.6211.060.34430.34432.306.170.35620.42286.291,731,471.005.3115.585.6617.2295.5096.6914.9133.2312.14--0.03270.00-13.1612.24-40.89--47.93--
Transgene SA266.82m-780.40m4.39bn158.00--7.99--16.47-0.2227-0.22270.07590.15530.1368--4.2848,316.46-40.00-24.81-50.27-29.79-----292.48-193.24----0.4764---23.681.5131.94--14.44--
Oryzon Genomics SA0.00-100.30m4.42bn44.00--1.49-----0.0431-0.04310.001.340.00101.09--0.00-2.72-4.20-3.19-4.82--------0.8741-3.160.1487------20.76--15.52--
Santhera Pharmaceuticals Holding AG3.69bn1.96bn4.45bn46.00--1.85--1.21-17.28-17.289.145.341.193.3763.69--63.20-33.83136.70-52.5696.8786.7452.99-79.400.753.570.2628--1,283.3326.70177.08--1.87--
Molecular Partners AG240.34m-2.09bn4.46bn168.00--0.663--18.54-1.78-1.780.20435.13------40,035.71---11.83---14.69--99.28-870.22-45.30----0.0195---96.29-7.43-152.59---1.40--
Adocia SA75.15m-739.65m4.53bn78.00------60.27-1.93-1.930.194-0.49080.07742.627.4427,564.10-76.16-43.08-396.14-72.937.91---984.28-514.531.01-2.072.12---81.22-46.13-206.65---27.60--
Futura Medical PLC127.37m-267.51m4.62bn12.00--20.55--36.31-0.0219-0.02190.01050.01820.3391--5.09258,414.20-71.22-79.25-127.75-127.2257.22---210.03-914.371.47--0.00-------11.40--219.68--
Heidelberg Pharma AG316.35m-638.82m4.71bn98.00--2.99--14.88-0.3957-0.39570.1960.9680.12220.218711.8795,273.69-24.68-43.91-33.18-64.3479.7552.13-201.94-206.242.22--0.104---46.7521.87-3.27---0.8341--
Turk Ilac Ve Serum Sanayi AS1.91bn105.72m4.73bn439.0044.723.8534.192.470.65340.653411.827.601.2832.393.394,358,227.007.073.1811.065.5222.4323.445.532.361.201.670.250.0016.8881.44229.4749.0037.65--
Devyser Diagnostics AB552.67m-140.54m5.21bn124.00--4.54--9.43-2.83-2.8311.1323.000.36711.565.111,529,661.00-9.33-8.97-10.65-10.1584.7680.14-25.43-23.914.34--0.1543--33.7128.59-16.64--44.59--
Eurobio Scientific SA4.54bn168.99m5.23bn137.0033.840.91128.321.150.43150.431511.5916.020.40183.194.31948,927.001.4916.911.8021.5347.1150.953.7223.342.324.030.36660.00-14.8120.80-80.61--20.02--
Lavipharm SA1.78bn69.83m5.38bn189.0077.063.6018.033.020.01190.01120.30340.25460.44492.212.62269,465.601.743.472.715.5845.5542.923.925.760.86083.060.4308--10.708.38139.579.8531.88--
Photocure ASA1.57bn14.81m5.46bn102.00373.903.6853.713.470.17550.175519.0217.820.72150.91447.935,024,010.000.6789-3.060.7682-3.5494.6593.640.941-5.154.33--0.00--27.3522.50101.36--49.83--
Faron Pharmaceuticals Oy0.00-1.08bn5.47bn34.00---------0.4038-0.40380.00-0.18760.00----0.00-287.97-213.06---963.12-----------12.02---------7.71---16.05--
Data as of May 31 2024. Currency figures normalised to Turk Ilac ve Serum Sanayi AS's reporting currency: Turkish Lira TRY

Institutional shareholders

0.10%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 09 May 202487.18k0.05%
Dimensional Fund Advisors Ltd.as of 30 Nov 202340.83k0.03%
AK Asset Management ASas of 30 Jun 202235.00k0.02%
DFA Australia Ltd.as of 31 Dec 2023323.000.00%
More ▼
Data from 30 Jun 2022 - 30 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.